Famitinib + Ifosfamide + Camrelizumab
Phase 1/2Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 24/100
24
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Effect of Drugs
Conditions
Effect of Drugs, Progression, Pediatric Cancer
Trial Timeline
Aug 15, 2019 → Sep 30, 2022
NCT ID
NCT04044378About Famitinib + Ifosfamide + Camrelizumab
Famitinib + Ifosfamide + Camrelizumab is a phase 1/2 stage product being developed by Jiangsu Hengrui Medicine for Effect of Drugs. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04044378. Target conditions include Effect of Drugs, Progression, Pediatric Cancer.
What happened to similar drugs?
2 of 4 similar drugs in Effect of Drugs were approved
Approved (2) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
9
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04044378 | Phase 1/2 | Withdrawn |
Competing Products
20 competing products in Effect of Drugs